カテゴリー： QYResearch, 世界

胞巣状横紋筋肉腫治療の世界市場：規模・現状・予測2019-2025

【英語タイトル】Global Alveolar Rhabdomyosarcoma Treatment Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料（DATA909X18151）・商品コード：DATA909X18151
・発行会社（調査会社）：QYResearch
・発行日：2019年11月25日（※2024年版があります。お問い合わせください）
・ページ数：99
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥577,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥865,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥1,154,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※当調査レポートでは、胞巣状横紋筋肉腫治療の世界市場について調査・分析し、胞巣状横紋筋肉腫治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（外科手術、化学療法、放射線療法）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。


・レポートの概要
・世界の胞巣状横紋筋肉腫治療市場動向
・主要企業別マーケットシェア
・胞巣状横紋筋肉腫治療の種類別市場規模2014-2019
（外科手術、化学療法、放射線療法）
・胞巣状横紋筋肉腫治療の用途別市場規模2014-2019
（病院、クリニック、その他）
・胞巣状横紋筋肉腫治療の北米市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療のヨーロッパ市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療の中国市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療の日本国内市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療の東南アジア市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療のインド市場：主要企業・種類別/用途別市場規模
・胞巣状横紋筋肉腫治療の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（Eli Lilly、GlaxoSmithKline、Boehringer Ingelheim、Bristol-Myers Squibb、Roche、Oasmia、Celgene、Pfizer、Johnson & Johnson）
・胞巣状横紋筋肉腫治療の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...
【レポートの概要】

Alveolar rhabdomyosarcoma (ARMS) is a type of soft tissue sarcoma that originates from the connective tissues of the body such as bone, muscle, cartilage, and ligaments.In 2018, the global Alveolar Rhabdomyosarcoma Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Alveolar Rhabdomyosarcoma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alveolar Rhabdomyosarcoma Treatment development in North America, Europe and Asia-Pacific.

The key players covered in this study
Eli Lilly
GlaxoSmithKline
Boehringer Ingelheim
Bristol-Myers Squibb
Roche
Oasmia
Celgene
Pfizer
Johnson & Johnson

Market segment by Type, the product can be split into
Surgical Operation
Chemotherapy
Radiotherapy

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
Asia-Pacific

The study objectives of this report are:
To analyze global Alveolar Rhabdomyosarcoma Treatment status, future forecast, growth opportunity, key market and key players.
To present the Alveolar Rhabdomyosarcoma Treatment development in North America, Europe and Asia-Pacific.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Alveolar Rhabdomyosarcoma Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Alveolar Rhabdomyosarcoma Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Surgical Operation
1.4.3 Chemotherapy
1.4.4 Radiotherapy
1.5 Market by Application
1.5.1 Global Alveolar Rhabdomyosarcoma Treatment Market Share by Application (2019-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Alveolar Rhabdomyosarcoma Treatment Market Size
2.2 Alveolar Rhabdomyosarcoma Treatment Growth Trends by Regions
2.2.1 Alveolar Rhabdomyosarcoma Treatment Market Size by Regions (2019-2025)
2.2.2 Alveolar Rhabdomyosarcoma Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Alveolar Rhabdomyosarcoma Treatment Market Size by by Players
3.1.1 Global Alveolar Rhabdomyosarcoma Treatment Revenue by by Players (2014-2019)
3.1.2 Global Alveolar Rhabdomyosarcoma Treatment Revenue Market Share by by Players (2014-2019)
3.1.3 Global Alveolar Rhabdomyosarcoma Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Alveolar Rhabdomyosarcoma Treatment Key Players Head office and Area Served
3.3 Key Players Alveolar Rhabdomyosarcoma Treatment Product/Solution/Service
3.4 Date of Enter into Alveolar Rhabdomyosarcoma Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Alveolar Rhabdomyosarcoma Treatment Market Size by Type (2014-2019)
4.2 Global Alveolar Rhabdomyosarcoma Treatment Market Size by Application (2014-2019)

5 North America
5.1 North America Alveolar Rhabdomyosarcoma Treatment Market Size (2014-2019)
5.2 Alveolar Rhabdomyosarcoma Treatment Key Players in North America
5.3 North America Alveolar Rhabdomyosarcoma Treatment Market Size by Type
5.4 North America Alveolar Rhabdomyosarcoma Treatment Market Size by Application

6 Europe
6.1 Europe Alveolar Rhabdomyosarcoma Treatment Market Size (2014-2019)
6.2 Alveolar Rhabdomyosarcoma Treatment Key Players in Europe
6.3 Europe Alveolar Rhabdomyosarcoma Treatment Market Size by Type
6.4 Europe Alveolar Rhabdomyosarcoma Treatment Market Size by Application

7 Asia-Pacific
7.1 Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size (2014-2019)
7.2 Alveolar Rhabdomyosarcoma Treatment Key Players in Asia-Pacific
7.3 Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size by Type
7.4 Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size by Application

8 International Players Profiles
8.1 Eli Lilly
8.1.1 Eli Lilly Company Details
8.1.2 Company Description and Business Overview
8.1.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.1.4 Eli Lilly Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019))
8.1.5 Eli Lilly Recent Development
8.2 GlaxoSmithKline
8.2.1 GlaxoSmithKline Company Details
8.2.2 Company Description and Business Overview
8.2.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.2.4 GlaxoSmithKline Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.2.5 GlaxoSmithKline Recent Development
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim Company Details
8.3.2 Company Description and Business Overview
8.3.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.3.4 Boehringer Ingelheim Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.3.5 Boehringer Ingelheim Recent Development
8.4 Bristol-Myers Squibb
8.4.1 Bristol-Myers Squibb Company Details
8.4.2 Company Description and Business Overview
8.4.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.4.4 Bristol-Myers Squibb Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.4.5 Bristol-Myers Squibb Recent Development
8.5 Roche
8.5.1 Roche Company Details
8.5.2 Company Description and Business Overview
8.5.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.5.4 Roche Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.5.5 Roche Recent Development
8.6 Oasmia
8.6.1 Oasmia Company Details
8.6.2 Company Description and Business Overview
8.6.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.6.4 Oasmia Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.6.5 Oasmia Recent Development
8.7 Celgene
8.7.1 Celgene Company Details
8.7.2 Company Description and Business Overview
8.7.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.7.4 Celgene Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.7.5 Celgene Recent Development
8.8 Pfizer
8.8.1 Pfizer Company Details
8.8.2 Company Description and Business Overview
8.8.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.8.4 Pfizer Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.8.5 Pfizer Recent Development
8.9 Johnson & Johnson
8.9.1 Johnson & Johnson Company Details
8.9.2 Company Description and Business Overview
8.9.3 Alveolar Rhabdomyosarcoma Treatment Introduction
8.9.4 Johnson & Johnson Revenue in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
8.9.5 Johnson & Johnson Recent Development

9 Market Forecast 2019-2025
9.1 Market Size Forecast by Product (2019-2025)
9.2 Market Size Forecast by Application (2019-2025)
9.3 Market Size Forecast by Regions
9.4 North America
9.5 Europe
9.6 Asia-Pacific

10 Analyst’s Viewpoints/Conclusions

11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Disclaimer
11.3 Author Details

List of Tables and Figures

Table Alveolar Rhabdomyosarcoma Treatment Key Market Segments
Table Key Players Alveolar Rhabdomyosarcoma Treatment Covered
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Surgical Operation Figures
Table Key Players of Surgical Operation
Figuer Chemotherapy Figures
Table Key Players of Chemotherapy
Figuer Radiotherapy Figures
Table Key Players of Radiotherapy
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Share by Application in 2018 & 2025
Figure Hospitals Case Studies
Figure Clinics Case Studies
Figure Others Case Studies
Figure Alveolar Rhabdomyosarcoma Treatment Report Years Considered
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Share by Regions 2014-2019
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Share by Regions 2014-2019
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Alveolar Rhabdomyosarcoma Treatment Revenue by by Players (2014-2019) (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Share by by Players (2014-2019)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Share by by Players in 2018
Table Global Alveolar Rhabdomyosarcoma Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Alveolar Rhabdomyosarcoma Treatment Product/Solution/Service
Table Date of Enter into Alveolar Rhabdomyosarcoma Treatment Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Type (2014-2019) (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size Share by Type (2014-2019)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size Market Share by Type (2014-2019)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Application (2014-2019) (Million US$)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size Share by Application (2014-2019)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size Market Share by Application (2014-2019)
Figure Global Alveolar Rhabdomyosarcoma Treatment Revenue Market Share by Application in 2018
Figure North America Alveolar Rhabdomyosarcoma Treatment Market Size 2014-2019 (Million US$)
Table North America Key Players Alveolar Rhabdomyosarcoma Treatment Revenue (2018-2019) (Million US$)
Table North America Key Players Alveolar Rhabdomyosarcoma Treatment Market Share (2018-2019)
Table North America Alveolar Rhabdomyosarcoma Treatment Market Size by Type 2014-2019 (Million US$)
Table North America Alveolar Rhabdomyosarcoma Treatment Market Share by Type 2014-2019
Table North America Alveolar Rhabdomyosarcoma Treatment Market Size by Application 2014-2019 (Million US$)
Table North America Alveolar Rhabdomyosarcoma Treatment Market Share by Application 2014-2019
Figure Europe Alveolar Rhabdomyosarcoma Treatment Market Size 2014-2019 (Million US$)
Table Europe Key Players Alveolar Rhabdomyosarcoma Treatment Revenue (2018-2019) (Million US$)
Table Europe Key Players Alveolar Rhabdomyosarcoma Treatment Market Share (2018-2019)
Table Europe Alveolar Rhabdomyosarcoma Treatment Market Size by Type 2014-2019 (Million US$)
Table Europe Alveolar Rhabdomyosarcoma Treatment Market Share by Type 2014-2019
Table Europe Alveolar Rhabdomyosarcoma Treatment Market Size by Application 2014-2019 (Million US$)
Table Europe Alveolar Rhabdomyosarcoma Treatment Market Share by Application 2014-2019
Figure Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size 2014-2019 (Million US$)
Table Asia-Pacific Key Players Alveolar Rhabdomyosarcoma Treatment Revenue (2018-2019) (Million US$)
Table Asia-Pacific Key Players Alveolar Rhabdomyosarcoma Treatment Market Share (2018-2019)
Table Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size by Type 2014-2019 (Million US$)
Table Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Share by Type 2014-2019
Table Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size by Application 2014-2019 (Million US$)
Table Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Share by Application 2014-2019
Table Eli Lilly Company Details
Table Eli Lilly Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Eli Lilly Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Eli Lilly Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure GlaxoSmithKline Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table GlaxoSmithKline Recent Development
Table Boehringer Ingelheim Company Details
Table Boehringer Ingelheim Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Boehringer Ingelheim Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Boehringer Ingelheim Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Roche Company Details
Table Roche Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Roche Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Roche Recent Development
Table Oasmia Company Details
Table Oasmia Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Oasmia Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Oasmia Recent Development
Table Celgene Company Details
Table Celgene Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Celgene Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Celgene Recent Development
Table Pfizer Company Details
Table Pfizer Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Pfizer Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Pfizer Recent Development
Table Johnson & Johnson Company Details
Table Johnson & Johnson Revenue in Alveolar Rhabdomyosarcoma Treatment Business 2014-2019 (Million US$)
Figure Johnson & Johnson Revenue Growth Rate in Alveolar Rhabdomyosarcoma Treatment Business (2014-2019)
Table Johnson & Johnson Recent Development
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Regions (Million US$) 2019-2025
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size Share by Regions (2019-2025)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size Share by Regions in 2025
Figure North America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Europe Alveolar Rhabdomyosarcoma Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Asia-Pacific Alveolar Rhabdomyosarcoma Treatment Market Size Forecast (2019-2025)(Million USD)
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Product (2019-2025) (Million US$)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size by Product (2019-2025)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size by Product in 2025
Table Global Alveolar Rhabdomyosarcoma Treatment Market Size by Application (2019-2025) (Million US$)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size by Application (2019-2025)
Figure Global Alveolar Rhabdomyosarcoma Treatment Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Eli Lilly、GlaxoSmithKline、Boehringer Ingelheim、Bristol-Myers Squibb、Roche、Oasmia、Celgene、Pfizer、Johnson & Johnson

★調査レポート[胞巣状横紋筋肉腫治療の世界市場：規模・現状・予測2019-2025] (コード：DATA909X18151)販売に関する免責事項を必ずご確認ください。
★調査レポート[胞巣状横紋筋肉腫治療の世界市場：規模・現状・予測2019-2025]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 胆道閉鎖症治療の世界市場：規模・現状・予測2019-2025
    DATA909X18226 / QYResearch / 2019年11月25日 / ※当調査レポートでは、胆道閉鎖症治療の世界市場について調査・分析し、胆道閉鎖症治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（薬物治療、外科治療）、用途別（病院、診療所、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の胆道閉鎖症治療市場動向 ・主要企業別マーケットシェア ・胆道閉鎖症治療の種類別市場規模2014-2019 （薬物治療、外科治療） ・胆道閉鎖症治療の用途別市場規模2014-2019 （病院、診療所、その他） ・胆道閉鎖症治療の北米市場：主要企業・種類別/用途別市場規模 ・胆道閉鎖症治療のヨーロッパ市場：主要企業・種類別/用途別市場規模...Biliary atresia or extra hepatic ductopenia is an acquired disease of the liver. This disease is characterized by the obliteration of the extra hepatic biliary system which results in obstruction of the bile flow from the liver to gall bladder.In 2018, the global Biliary Atresia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Biliary Atresia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Biliary...
  • 慢性片頭痛治療の世界市場：規模・現状・予測2019-2025
    DATA909X18277 / QYResearch / 2019年11月25日 / ※当調査レポートでは、慢性片頭痛治療の世界市場について調査・分析し、慢性片頭痛治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（薬物治療、代替治療）、用途別（病院、診療所、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の慢性片頭痛治療市場動向 ・主要企業別マーケットシェア ・慢性片頭痛治療の種類別市場規模2014-2019 （薬物治療、代替治療） ・慢性片頭痛治療の用途別市場規模2014-2019 （病院、診療所、その他） ・慢性片頭痛治療の北米市場：主要企業・種類別/用途別市場規模 ・慢性片頭痛治療のヨーロッパ市場：主要企業・種類別/用途別市場規模...Migraine is a painful, episodic disease that sometimes develops into a chronic condition. It is one of the most common neurological diseases in clinical practice. Chronic migraines (CM) are a natural progression of chronic migraines, with a frequency of 15 days per month and similar characteristics to migraine attacks.In 2018, the global Chronic Migraine Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Chronic Migraine Treatment status, future forecast, growth opportunity, key market and key...

    • ◆H&Iグローバルリサーチのお客様（例）◆